- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04619420
Um estudo de JNJ-63733657 em participantes com doença de Alzheimer precoce (Autonomy)
Um estudo randomizado, duplo-cego, controlado por placebo, de grupo paralelo, multicêntrico para avaliar a eficácia e a segurança de JNJ-63733657, um anticorpo monoclonal anti-tau, em participantes com doença de Alzheimer precoce
The primary purpose of this study is to evaluate the effect of JNJ-63733657 versus placebo on clinical decline as measured by the Integrated Alzheimer's Disease Rating Scale (iADRS), a composite of cognition and function.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
-
Adelaide, Austrália, 5000
- Royal Adelaide Hospital
-
Box Hill, Austrália, 3128
- Box Hill Hospital
-
Carlton, Austrália, 3053
- Neuro Trials Victoria
-
Ivanhoe, Austrália, 3079
- Austin Health
-
Malvern, Austrália, 3144
- HammondCare Neurodegenerative Clinical Trials - VIC
-
Nedlands, Austrália, 6009
- Australian Alzheimer's Research Foundation Incorporated
-
Parkville, Austrália, 3050
- Royal Melbourne Hospital
-
-
-
-
-
Bruges, Bélgica, 8000
- AZ St.-Jan Brugge-Oostende AV
-
Brussels, Bélgica, 1200
- UCL Hopital Saint-Luc
-
Edegem, Bélgica, 2650
- UZ Antwerpen
-
Ghent, Bélgica, 9000
- Universitair Ziekenhuis Gent
-
Hasselt, Bélgica, 3500
- Jessa Ziekenhuis
-
Jette, Bélgica, 1090
- UZ Brussel
-
Leuven, Bélgica, 3000
- UZ Leuven
-
Roeselare, Bélgica, 8800
- Algemeen Ziekenhuis Delta
-
-
-
-
Ontario
-
London, Ontario, Canadá, N6C 0A7
- Parkwood Institute
-
Peterborough, Ontario, Canadá, K9H 2P4
- Kawartha Centre - Redefining Healthy Aging
-
Toronto, Ontario, Canadá, M3B 257
- Toronto Memory Program (Neurology Research Inc.)
-
Toronto, Ontario, Canadá, M5T 2S8
- UHN-Toronto Western Hospital
-
-
Quebec
-
Montreal, Quebec, Canadá, H3A 2B4
- McGill University
-
-
-
-
-
Algorta - Getxo, Espanha, 48993
- Centro At. Esp. Oroitu
-
Barcelona, Espanha, 08025
- Hosp. de La Santa Creu I Sant Pau
-
Barcelona, Espanha, 08003
- Hosp. Del Mar
-
Barcelona, Espanha, 08028
- Fund. Ace-Inst. Cat. Neuroc. Aplicades
-
Barcelona, Espanha, 08195
- Idc Salud Hosp. Gral. de Catalunya
-
Lleida, Espanha, 25198
- Hosp. Univ. Santa Maria
-
Madrid, Espanha, 28040
- Hosp. Clinico San Carlos
-
Terrassa, Espanha, 08221
- Hosp. Mutua Terrassa
-
Valencia, Espanha, 46026
- Hosp. Univ. I Politecni La Fe
-
-
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35233
- University of Alabama Birmingham
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85013
- Dignity Health
-
-
California
-
Irvine, California, Estados Unidos, 92614
- Irvine Clinical Research
-
La Jolla, California, Estados Unidos, 92037
- University of California San Diego Medical Center
-
Los Angeles, California, Estados Unidos, 90095
- University of California - Los Angeles
-
Palo Alto, California, Estados Unidos, 94304
- Stanford University Medical Center
-
San Diego, California, Estados Unidos, 92103
- Pacific Research Network Prn
-
Santa Ana, California, Estados Unidos, 92705
- Syrentis Clinical Research
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06510
- Yale University School Of Medicine
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 20007
- Georgetown University Clinical Research Unit CRU
-
-
Florida
-
Atlantis, Florida, Estados Unidos, 33462
- JEM Research LLC
-
Delray Beach, Florida, Estados Unidos, 33445
- Brain Matters Research
-
Fort Myers, Florida, Estados Unidos, 33912
- Neuropsychiatric Research Center of SWFL
-
Jacksonville, Florida, Estados Unidos, 32256
- Clinical NeuroScience Solutions Inc
-
Jupiter, Florida, Estados Unidos, 33458
- Alphab Global Research
-
Maitland, Florida, Estados Unidos, 32751
- K2 Medical Research
-
Maitland, Florida, Estados Unidos, 32751
- Tandem Intermediate LLC
-
Merritt Island, Florida, Estados Unidos, 32952
- Merritt Island Medical Research, LLC
-
Miami, Florida, Estados Unidos, 33136
- University of Miami Miller School of Medicine
-
Miami, Florida, Estados Unidos, 33137
- Miami Jewish Health System
-
Naples, Florida, Estados Unidos, 34105
- Aqualane Clinical Research
-
Ocala, Florida, Estados Unidos, 34470
- Renstar Medical Research
-
Ocoee, Florida, Estados Unidos, 34761
- Sensible Healthcare
-
Tampa, Florida, Estados Unidos, 33609
- Axiom Clinical Research of Florida
-
Tampa, Florida, Estados Unidos, 33613
- Stedman Clinical Trials
-
Tampa, Florida, Estados Unidos, 33613
- University of South Florida - Health Byrd Alzheimer Institute
-
The Villages, Florida, Estados Unidos, 32162
- Charter Research
-
Viera, Florida, Estados Unidos, 32904
- ClinCloud Clinical Research
-
Wellington, Florida, Estados Unidos, 33414
- Alzheimers Research and Treatment Center
-
West Palm Beach, Florida, Estados Unidos, 33407
- Palm Beach Neurology and Premier Research Institute
-
Winter Park, Florida, Estados Unidos, 32789
- Conquest Research
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30329
- The Emory Clinic
-
Decatur, Georgia, Estados Unidos, 30030
- Sandhill Research
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60640
- Great Lakes Clinical Trials
-
Elk Grove Village, Illinois, Estados Unidos, 60007
- Alexian Brothers Medical Center - Neuroscience Research Institute
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Indiana University
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, Estados Unidos, 02114
- Massachusetts General Hospital
-
Braintree, Massachusetts, Estados Unidos, 02184
- Anil Nair dba Alzheimer's Disease Center
-
-
Mississippi
-
Hattiesburg, Mississippi, Estados Unidos, 39401
- Hattiesburg Clinic
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Washington University School Of Medicine
-
-
New Jersey
-
Mount Arlington, New Jersey, Estados Unidos, 07856
- NeuroCognitive Institute
-
Princeton, New Jersey, Estados Unidos, 08540
- Princeton Medical Institute
-
Toms River, New Jersey, Estados Unidos, 08755
- Advanced Memory Research Institute of NJ
-
-
New York
-
Albany, New York, Estados Unidos, 12208
- Neurological Associates of Albany, PC
-
East Syracuse, New York, Estados Unidos, 13057
- Velocity Clinical Research
-
New York, New York, Estados Unidos, 10016
- New York University Medical Center
-
-
North Carolina
-
Winston-Salem, North Carolina, Estados Unidos, 27157
- Wake Forest Health Sciences
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44195
- Cleveland Clinic Lou Revo Center for Brain Health
-
Columbus, Ohio, Estados Unidos, 43221
- Wexner Medical Center at the Ohio State University
-
-
Pennsylvania
-
Plymouth Meeting, Pennsylvania, Estados Unidos, 19462
- Keystone Clinical Studies LLC
-
-
Rhode Island
-
Providence, Rhode Island, Estados Unidos, 02906
- Brown University School of Medicine
-
-
Texas
-
Houston, Texas, Estados Unidos, 77054
- The University of Texas Health Science Center at Houston
-
-
Vermont
-
Bennington, Vermont, Estados Unidos, 05201
- Memory Clinic Inc
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22903
- University of Virginia
-
-
-
-
-
Bordeaux, França, 33076
- Hopital Pellegrin CHU Bordeaux
-
Lille, França, 59037
- Hopital Roger Salengro - CHU Lille
-
Nantes, França, 44093
- CHU Nantes - Hopital Nord Laënnec
-
Paris, França, 75010
- Hopital Lariboisiere-Fernand Widal
-
Paris, França, 75013
- Hopital Pitie Salpetriere
-
Rennes, França, 35009
- Chu Rennes Hopital Pontchaillou
-
Rouen, França, 76031
- Hopital Charles Nicolle
-
Toulouse, França, 31059
- CHU Toulouse - Hôpital La Grave
-
Tours, França, 37000
- Hôpital Bretonneau
-
-
-
-
-
's-Hertogenbosch, Holanda, 5223 LA
- BRC - Den Bosch
-
Amsterdam, Holanda, 1081 GN
- BRC - Amsterdam
-
Leeuwarden, Holanda, 8934AD
- QPS Netherlands
-
Zwolle, Holanda, 8052 AZ
- BRC Zwolle
-
-
-
-
-
Aizu-Wakamatsu, Japão, 965-8585
- Takeda General Hospital
-
Chiba, Japão, 263-0043
- Inage Neurology and Memory Clinic
-
Fujisawa-shi, Japão, 251-0038
- Kawashima Neurology Clinic
-
Fukuoka, Japão, 814-0180
- Fukuoka University Hospital
-
Hachiōji, Japão, 192-0071
- Keikokai P-One Clinic
-
Himeji, Japão, 672-8043
- Himeji Central Hospital Clinic
-
Kamakura-shi, Japão, 247-8533
- Shonan Kamakura General Hospital
-
Kanzaki-gun, Japão, 842-0192
- National Hospital Organization Hizen Psychiatric Center
-
Kawasaki, Japão, 210-0852
- Koukan Clinic
-
Kobe, Japão, 650-0047
- Kobe City Medical Center General Hospital
-
Kurashiki-shi, Japão, 7100813
- Rijikai Medical Corporation Katayama Medical Clinic
-
Kurume, Japão, 830-0011
- Kurume University Hospital
-
Kyoto, Japão, 607-8062
- Rakuwakai Otowa Hospital
-
Kyoto, Japão, 607-8113
- Rakuwakai Otowa Rehabilitation Hospital
-
Narashino, Japão, 275-0006
- Saiseikai Narashino Hospital
-
Obu-shi, Japão, 474-8511
- National Center For Geriatrics And Gerontology
-
Shinjuku-ku, Japão, 162-0053
- Clinical Research Hospital Tokyo
-
Tokyo, Japão, 160-0023
- Tokyo Medical University Hospital
-
Tokyo, Japão, 173-0015
- Tokyo Metropolitan Geriatric Hospital
-
Toyonaka-shi, Japão, 560-0004
- Nagomi Clinic
-
Toyonaka-shi, Japão, 5600004
- Jinsenkai MI Clinic
-
Yokohama, Japão, 235-0012
- Yokohama Brain and Spine Center
-
-
-
-
-
Bath, Reino Unido, BA1 3NG
- Royal United Hospital
-
London, Reino Unido, W6 8RF
- Charing Cross Hospital
-
-
-
-
-
Stockholm, Suécia, 14186
- Karolinska Universitetssjukhuset
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Early Alzheimer's disease (AD): Gradual and progressive subjective decline in the participant's cognition over at least the past 6 months, as reported by the participant and informant (study partner) and Clinical Dementia Rating-Global Score (CDR-GS) of 0.5 and memory box score greater than or equal to (>=) 0.5 at screening
- Participants must have positive tau PET results
- Able to read and write and with a minimum 5 years of formal education as reported by participant and study partner at screening
- Have a designated study partner who has adequate literacy to participate and be judged to have high likelihood of completing the study with the participant
- Male participants must agree not to donate sperm for the purpose of reproduction during the study and up to 16 weeks after receiving the last dose of study intervention
Exclusion Criteria:
- Participants with CDR GS >=2 at predose baseline Clinical Dementia Rating (CDR) administration
- Participants who fulfill diagnostic criteria for Mild Cognitive Impairment (MCI) or dementia/mild or major neurocognitive disorder suspected to be due to any etiology other than AD (example, Parkinson's disease, cerebrovascular disease, normal pressure hydrocephalus, head injury, drug or alcohol abuse/dependence, anoxic brain injury, (Et cetera[etc])
- Geriatric Depression Scale (GDS) 30 score greater than (>) 12
- Hachinski Ischemic Scale (HIS) >4
- Has received medications that affect the central nervous system (CNS), except treatments for AD, for less than 2 months; that is, doses of chronic medications that effect the CNS should be stable for at least 2 months before the start of screening. If a participant has recently stopped a chronic medication that effects the CNS, he or she must have discontinued treatment at least 2 months before the start of screening. Chronic use of benzodiazepines is not permitted
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: JNJ-63733657 Low-dose
Participants will receive single dose of JNJ-63733657 low-dose administered by intravenous (IV) infusion every 4 weeks during the double-blind treatment period. Participants will have an option to continue with the long-term extension (LTE) phase of the trial and will continue to receive the same treatment and dose during the LTE treatment period. |
JNJ-63733657 low or high dose will be administered by IV infusion. |
|
Experimental: JNJ-63733657 High-dose
Participants will receive single dose of JNJ-63733657 high-dose administered by IV infusion every 4 weeks during double-blind treatment period. Participants will have an option to continue with the LTE phase of the trial and will continue to receive the same treatment and dose during the LTE treatment period. |
JNJ-63733657 low or high dose will be administered by IV infusion. |
|
Comparador de Placebo: Placebo
Participants will receive single dose of matching placebo to JNJ-63733657 administered by IV infusion every 4 weeks during double-blind treatment period. Participants will have an option to continue with the LTE phase of the trial and will be re-randomized in a 1:1 ratio to receive either JNJ-63733657 low-dose or JNJ-63733657 high-dose during the LTE treatment period. |
Placebo matching to JNJ-63733657 will be administered by IV infusion. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Double-blind (DB) Treatment Period: Change From Baseline in Integrated Alzheimer's Disease Rating Scale for Mild Cognitive Impairment (iADRS-MCI) Total Score at Week 104
Prazo: Baseline (Day 1), Week 104
|
The iADRS-MCI was a composite measure of cognition and function. It was originally developed as a combination of the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) 14-item cognition subscale and the instrumental activities of daily living (ADL) items from the Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) scale. It was calculated as a linear combination of total scores of the 2 individual components. The iADRS-MCI total score was derived as a combination of the ADAS-Cog13 total score (ranging from 0 to 85, with higher scores indicating worse cognitive performance) and the ADCS-ADL-MCI total score (ranging from 0 to 53, with lower scores indicating worse daily function). Therefore, the iADRS-MCI total score was calculated as [-1(ADAS-Cog13 score)+85] + ADCS-ADL-MCI score, ranging from 0 to 138, with lower scores indicating worse performance. |
Baseline (Day 1), Week 104
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Double-blind (DB) Treatment Period: Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive, 13-item Version (ADAS-Cog13) Total Score at Week 104
Prazo: Baseline (Day 1), Week 104
|
The ADAS-Cog was a rater administered instrument that was designed to assess the severity of dysfunction in cognition characteristic of persons with Alzheimer's Disease (AD). The ADAS-Cog13 item scale includes all items from the original ADAS-Cog11 (consisting of 11 tasks measuring the disturbances of memory, language, praxis, attention, and other cognitive abilities, often referred to as the core symptoms of AD) in addition of number cancellation task and a delayed free recall task, for a total of 85 points (0 to 85), with higher scores indicating worse cognitive performance. |
Baseline (Day 1), Week 104
|
|
Double-blind (DB) Treatment Period: Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living for Mild Cognitive Impairment (ADCS-ADL-MCI) Total Score at Week 104
Prazo: Baseline (Day 1), Week 104
|
The ADCS-ADL-MCI was a functional measure based on information provided by the study partner that describes the performance of participants in several activities of daily living. The ADCS-ADL-MCI scale consists of 17 instrumental items (example; shopping, preparing meals, using household appliances, etc) and 1 basic item (getting dressed). The ADCS-ADL-MCI scale version used in this study comprises 24 items of which 18 items are used for the standard analysis. The total score ranges from 0 to 53 with higher scores indicating less impairment. A positive change from baseline indicates healthy functioning while a negative change from baseline indicates a decline in independent functioning. |
Baseline (Day 1), Week 104
|
|
Double-blind (DB) Treatment Period: Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Scale Index Score at Week 88
Prazo: Baseline (Day 1), Week 88
|
The RBANS was a battery developed for cognitive assessment, detection, and characterization of dementia. RBANS includes 12 subtests that are divided into 5 RBANS indices: Immediate memory (list learning and story memory), visuospatial/constructional (figure copy and line orientation), language (picture naming and semantic fluency), attention (digit span and coding) and delayed memory (list recall, list recognition, story recall, and figure recall). Index scores are expressed as an age-adjusted standard score with a normal mean of 100 and an standard deviation (SD) of 15. Sum of index scores was the sum of the 5 index scores, and the Sum of Index Scores was converted to an RBANS total scale index score via a mapping table. The RBANS total scale Index score was a norm-based t-score, based on a distribution with a mean of 100 and an SD of 15. Scores range from 40 to 160. Higher scores indicated better performance. |
Baseline (Day 1), Week 88
|
|
Double-blind (DB) Treatment Period: Change From Baseline in Each of the 5 Individuals RBANS Indices at Week 88
Prazo: Baseline (Day 1), Week 88
|
The RBANS was a battery developed for cognitive assessment, detection, and characterization of dementia. RBANS includes 12 subtests that are divided into 5 RBANS indices: Immediate memory (list learning and story memory), visuospatial/constructional (figure copy and line orientation), language (picture naming and semantic fluency), attention (digit span and coding) and delayed memory (list recall, list recognition, story recall, and figure recall). Index scores are expressed as an age-adjusted standard score with a normal mean of 100 and an standard deviation (SD) of 15. Sum of index scores was the sum of the 5 index scores, and the sum of index scores was converted to an RBANS total scale index score via a mapping table. The RBANS Total Scale Index Score was a norm-based t-score, based on a distribution with a mean of 100 and an SD of 15. Scores range from 40 to 160 each of the index scores. Higher scores indicated better performance. |
Baseline (Day 1), Week 88
|
|
Double-blind (DB) Treatment Period: Change From Baseline in Each of the 12 Subtests Comprising the RBANS at Week 88
Prazo: Baseline (Day 1), Week 88
|
The RBANS was a battery developed for cognitive assessment, detection, and characterization of dementia. RBANS includes 12 subtests that are divided into 5 RBANS indices: Immediate memory (list learning [0-40] and story memory [0-24]), visuospatial/constructional (figure copy [0-20] and line orientation [0-20]), language (picture naming [0-10] and semantic fluency [0-40]), attention (digit span [0-16] and coding [0-89]) and delayed memory (list recall [0-10], list recognition [0-20], story recall [0-12], and figure recall [0-20]). Index scores are expressed as an age-adjusted standard score with a normal mean of 100 and an SD of 15. Sum of index scores was the sum of the 5 index scores, and the Sum of Index Scores was converted to an RBANS total scale index score via a mapping table. Scores range from 40 to 160. Higher scores indicated better performance. |
Baseline (Day 1), Week 88
|
|
Double-blind (DB) Treatment Period: Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score at Week 104
Prazo: Baseline (Day 1), Week 104
|
The CDR was a subjectively rated outcome measure that serves as a global clinical staging instrument. Six domains were assessed and then synthesized to assign a Global CDR score. It included 3 cognitive and 3 functional domains: 1) memory, 2) orientation, 3) judgment and problem solving, 4) involvement in community affairs, 5) home and hobbies, and 6) personal care based on the CDR interview. The CDR was scored 2 ways yielding a global CDR score (CDR-GS and CDR-SB). CDR was an ordinal parameter (scale 0 [least impairment] to 3 [severe impairment]). The CDR-SB was the sum of the 6 domains which ranged from 0 (least impairment) to 18 (severe impairment). Higher scores indicated worse disease state. |
Baseline (Day 1), Week 104
|
|
Double-blind (DB) Treatment Period: Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Week 104
Prazo: Baseline (Day 1), Week 104
|
The NPI was a measure of psychobehavioral disturbances, assessing the frequency and severity of disturbances in 12 domains, based on a caregiver interview. For each domain, there was also an assessment of caregiver burden. Frequency for each domain was rated on a 4-point scale (from 1=rarely to 4=very often) and severity on a 3-point scale (from 1=mild to 3=severe), with the score for each domain being the product of the frequency and severity scores, such that each domain was scored from 1 to 12. The NPI total score was the sum of the 12 domain scores, ranged from 0 (best) to 144 (worst). Higher score indicated worst psychobehavior. |
Baseline (Day 1), Week 104
|
|
Double-blind (DB) Treatment Period: Percentage of Participants With Progression From Clinical Dementia Rating-Global Score (CDR-GS) 0 to 0.5 or Higher, 0.5 to 1 or Higher, and 1 to 2 or Higher
Prazo: From baseline (Day 1) up to Week 104
|
Percentage of participants with progression from CDR-GS 0 to 0.5 or higher, 0.5 to 1 or higher, and 1 to 2 or higher was reported. The CDR was a subjectively rated outcome measure that serves as a global clinical staging instrument. Six domains were assessed and then synthesized to assign a Global CDR score. It included 3 cognitive and 3 functional domains: (1) memory, (2) orientation, (3) judgment and problem solving, (4) involvement in community affairs, (5) home and hobbies, and (6) personal care based on the CDR interview. CDR was scored 2 ways yielding a global CDR score (CDR-GS and CDR-SB). CDR was an ordinal parameter (scale 0 [least impairment] to 3 [severe impairment]). The CDR-GS was derived based on an algorithm and was scored of 0 (normal), 0.5 (very mild dementia), 1 (mild dementia), 2 (moderate dementia), and 3 (severe dementia). Score ranges from 0 to 3 and a high score on CDR-GS indicated a high disease severity. |
From baseline (Day 1) up to Week 104
|
|
Double-blind (DB) Treatment Period: Change From Baseline in Brain Tau Burden as Measured by Tau Positron Emission Tomography (PET) at Week 104
Prazo: Baseline (Day 1), Week 104
|
Change from baseline in brain tau burden (tau naive composite Region of interest [ROI] standardized uptake value ratio [SUVR], cerebral cortex ROI SUVR, meta temporal ROI SUVR, spatial progression of tauopathy [SPOT] volume over cerebral cortex ROI) as measured by tau PET was reported. For tau naive ROI method, tau PET brain scans were assessed to measure change in SUVR over regions without evidence of tau burden at baseline (that is, within 1 standard deviation of a cognitively normal amyloid negative reference population). For SPOT method, tau PET brain scans were assessed to quantify extent of spread of tau by measuring difference in volume of elevated tau PET burden (defined as exceeding an SUVR threshold of 1.2) in cerebral cortex brain region at follow up versus that at baseline. Tau PET brain scans were assessed to measure spread of tau tangles using SUVR in cerebral cortex, meta temporal brain region, respectively. |
Baseline (Day 1), Week 104
|
|
Double-blind (DB) Treatment Period: Change From Baseline in Cerebrospinal Fluid (CSF) Concentrations of Total, Free, and Bound p217+Tau Fragments at Week 104
Prazo: Baseline (Day 1), Week 104
|
Change from baseline in CSF concentration of total, free, and bound p27+tau fragments at Week 104 was reported. |
Baseline (Day 1), Week 104
|
|
Double-blind (DB) Treatment Period: Cerebrospinal Fluid (CSF) Concentrations of JNJ-63733657
Prazo: Weeks 52, 104, and 208
|
CSF concentration of JNJ-63733657 was reported. |
Weeks 52, 104, and 208
|
|
Double-blind (DB) Treatment Period: Serum Concentrations of JNJ-63733657
Prazo: Baseline (Day 1), Weeks 4, 8, 12, 16, 20, 24, 36, 52, 76, 104, 128, 156, and 180
|
Serum concentration of JNJ-63733657 was reported. |
Baseline (Day 1), Weeks 4, 8, 12, 16, 20, 24, 36, 52, 76, 104, 128, 156, and 180
|
|
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent JNJ-63733657 Antidrug Antibodies (ADAs) in Serum
Prazo: Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
Number of participants with treatment-emergent JNJ-63733657 ADA in serum was reported. Any ADAs occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent. Participants with treatment-emergent antibodies to JNJ-63733657 included participants with treatment-induced antibodies to JNJ-63733657 and treatment-boosted antibodies to JNJ- 63733657. |
Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
|
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Prazo: Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Any AE occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent. |
Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
|
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
Prazo: Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Serious adverse event (SAE) was any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product. Any SAE occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent. |
Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
|
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Adverse Events of Special Interest (AESIs)
Prazo: Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Treatment-emergent AESIs were collected in the eCRF and examined separately, grouped in the following categories including: hepatobiliary disorders/Liver enzyme abnormality, and Infusion-related reactions. Any AESI occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent. |
Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
|
Double-blind (DB) Treatment Period: Number of Participants Who Discontinued Study Treatment Due to AEs
Prazo: Baseline (Day 1) up to Week 232
|
Number of participants who discontinued the study treatment due to AE was reported. |
Baseline (Day 1) up to Week 232
|
|
Double-blind (DB) Treatment Period: Change From Baseline in 12-lead Electrocardiogram (ECG) Parameter: ECG Mean Heart Rate Supine
Prazo: Baseline (Day 1), Weeks 4, 8, 12, 24, 36, 52, 76, 104, 128, 156, and 180
|
Change from baseline in 12-lead ECG parameter (ECG mean heart rate supine) was reported. |
Baseline (Day 1), Weeks 4, 8, 12, 24, 36, 52, 76, 104, 128, 156, and 180
|
|
Double-blind (DB) Treatment Period: Change From Baseline in 12-lead ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcB Interval, QTcF Interval, QTcL Interval, and RR Interval
Prazo: Baseline (Day 1), Weeks 4, 8, 12, 24, 36, 52, 76, 104, 128, 156, and 180
|
Change from baseline in 12-lead ECG parameter (PR interval, QRS duration, QT interval, QTcB interval, QTcF interval, QTcL interval and RR interval) was reported. |
Baseline (Day 1), Weeks 4, 8, 12, 24, 36, 52, 76, 104, 128, 156, and 180
|
|
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Abnormalities in Laboratory Parameters
Prazo: Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
Number of participants with treatment-emergent abnormalities in laboratory parameters (hematology, chemistry and urinalysis) were reported. Laboratory abnormalities meeting with lower limit of the normal range (LLN) and upper limit of the normal range (ULN) was reported. Any laboratory abnormalities occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent. |
Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
|
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Abnormal Findings in Neurological Examination
Prazo: Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
Number of participants with treatment-emergent abnormal findings in neurological examination (mental state, cranial nerves, motor ability: strength, tone, involuntary movements, coordination: finger-to-nose, gai, postural reflexes, sensation: proprioception, cold, light touch, deep tendon reflexes) was reported. Abnormalities in neurological examination was determined by the investigator. Any neurological abnormalities occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent. |
Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
|
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Abnormal Findings in Physical Examination
Prazo: Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
Number of participants with treatment-emergent abnormal findings in physical examination (general appearance, skin, eye, ear, nose, throat, heart, head, neck, thyroid, chest, lung, abdomen, musculoskeletal, breast, neurological) was reported. Abnormal findings in physical examination was determined by the investigator. Any physical abnormalities occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent. |
Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
|
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Potentially Clinically Significant Vital Signs
Prazo: Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
Number of participants with treatment-emergent potentially clinically significant vital signs including systolic blood pressure (standing and supine: less than (<) 90 millimeters of mercury (mmHg) and greater than (>) 180 mmHg), diastolic blood pressure (standing and supine: <50 mmHg and >105 mmHg), pulse (<45 bpm to >120 bpm), temperature (<35 degree Celsius and >38 degree Celsius) and weight (decrease of >=10% relative to baseline and increase of >=10% relative to baseline) were reported. Any clinically significant vital sign occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent. |
Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
|
Double-blind (DB) Treatment Period: Number of Participants With Brain Magnetic Resonance Imaging (MRI) Safety Findings
Prazo: From Day 1 up to Week 245
|
Number of participants with brain MRI safety findings was reported. MRI safety-related observations from the central imaging vendor including vasogenic edema, cerebral macrohemorrhages, cerebral superficial siderosis and other findings was reported. |
From Day 1 up to Week 245
|
|
Double-blind (DB) Treatment Period: Number of Participants With Shift From Baseline in Suicidal Ideation or Suicidal Behavior as Assessed by Columbia Suicidality Severity Rating Scale (C-SSRS)
Prazo: Baseline (Day 1) up to Week 245
|
C-SSRS was a clinician-rated instrument that reports severity and frequency of suicide-related ideation and behaviors. Suicidal ideation was classified on a 5-item scale: 1 (wish to be dead), 2 (non-specific active suicidal thoughts), 3 (suicidal ideation without plan and intent), 4 (suicidal ideation intent to act without plan), and 5 (suicidal ideation with plan and intent). Suicidal behavior was classified on a 5-item scale: 6 (preparatory acts or behavior), 7 (aborted attempt), 8 (interrupted attempt), 9 (actual attempt [non-fatal]), and 10 (suicide). Total score from 10 categories was summarized into 3 categories: No suicidal ideation or behavior(0), suicidal ideation (1-5), suicidal behavior (6-10). Total score ranged from 0 to 10. Higher scores indicated more severe suicidal ideation and behavior. |
Baseline (Day 1) up to Week 245
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CR108832
- 2020-000116-30 (Número EudraCT)
- 63733657ALZ2002 (Outro identificador: Janssen Research & Development, LLC)
- 2022-501188-42-00 (Identificador de registro: EUCT number)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .